Triple-negative breast cancer, characterized by the absence of ER, PR, and HER-2 expressions (Buyuk et al., 2022), constitutes 15%–20% of all breast cancer cases (Yao et al., 2017). Here, ESR1 is linked to triple-negative breast carcinoma.